Prentiss Smith & Co’s TherapeuticsMD TXMD Stock Holding History

Prentiss Smith & Co’s Portfolio TXMD Stock Details TXMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-60	Closed	-$18K	–	299
2017 Q4	$18K	Buy	+60	New	+$16.7K	0.01%	192

Other funds holding TXMD

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VOYA Investment Management Atlanta, Georgia $116B AUM 61.47% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Prentiss Smith & Co's TXMD Position: Q1 2018 in Review

Prentiss Smith & Co sold out of TherapeuticsMD (TXMD) in Q1 2018, closing a stake of 60 shares — an estimated $18K sold.

Prentiss Smith & Co first reported a position in TXMD in Q4 2017 and held it in 1 quarter. The position peaked at $18K in Q4 2017. 143 funds tracked by Wall St. Rank hold TXMD as of Q1 2018.

Prentiss Smith & Co reported no remaining TherapeuticsMD position as of Q1 2018 after selling out during the quarter.
Prentiss Smith & Co sold 60 TherapeuticsMD shares in Q1 2018, an estimated $18K.
Prentiss Smith & Co first reported a position in TherapeuticsMD in Q4 2017 and held it in 1 quarter.
Prentiss Smith & Co's TherapeuticsMD position peaked at $18K in Q4 2017.
143 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2018.

Based on Prentiss Smith & Co's 13F filing for Q1 2018, filed 20 Apr 2018.